Intrexon | XON - Ebitda


Intrexon reported $-24.7M in EBITDA for its fiscal quarter ending in June of 2024.





Ebitda Change Date
Agenus USD -10.11M 19.02M Mar/2025
Alaunos Therapeutics USD -21.02M 1.33M Mar/2021
Amgen USD 5.8B 1.25B Sep/2026
Anika Therapeutics USD 4.54M 3.67M Dec/2025
Arrowhead Research USD -147.68M 40.33M Jun/2026
AstraZeneca USD 7.46B 2.3B Sep/2026
Bristol-Myers Squibb USD 3.48B 1.6B Sep/2026
Gilead Sciences USD -9.31B 12.82B Jun/2026
GlaxoSmithKline GBP 3.51B 734M Jun/2026
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Incyte USD 778.57M 410.6M Jun/2026
Intrexon USD -24.7M 2.92M Jun/2024
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
Ligand Pharmaceuticals USD 74.27M 88.56M Jun/2026
MacroGenics USD -64.54M 34.34M Jun/2026
MannKind USD 2.47M 461K Jun/2026
Merck USD 1.42B 2.97B Jun/2026
Novartis USD 8.62B 2.14B Sep/2026
Rigel Pharmaceuticals USD -4.17M 798K Sep/2023
Roche Holding CHF 13.43B 744M Jun/2026
Thermo Fisher Scientific USD 3.79B 244M Sep/2026
Veracyte USD 41.24M 2.72M Sep/2026
Xencor USD 25.1M 59.73M Sep/2026